Seeking Alpha

Ono Pharmaceutical Co., Ltd. (OPHLF)

- Grey Market
  • Dec. 19, 2014, 11:19 AM
    • Gilead Sciences (GILD +1.1%) and Osaka, Japan-based Ono Pharmaceutical Company (OTC:OPHLF) (OTCPK:OPHLY) enter into an exclusive license agreement to develop and commercialize ONO-4059, Ono's oral Brutons tyrosine kinase (BTK) inhibitor, for the treatment of B-cell malignancies and other diseases.
    • Under the terms of the agreement, Gilead will pay Ono an upfront fee plus development, regulatory and commercial milestones.
    • Gilead will have exclusive rights to develop and commercialize ONO-4059 worldwide except Japan, South Korea, Taiwan, China and the ASEAN countries, where Ono retains development and commercialization rights.
Visit Seeking Alpha's
OPHLF vs. ETF Alternatives
Company Description
Production, purchase and sale of pharmaceuticals and diagnostic reagents focusing primarily on prescription pharmaceuticals
Sector: Healthcare
Country: Japan